These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 7949248)

  • 21. Bovine seminal ribonuclease exerts selective cytotoxicity toward neuroblastoma cells both sensitive and resistant to chemotherapeutic drugs.
    Cinatl J; Cinatl J; Kotchetkov R; Matousek J; Woodcock BG; Koehl U; Vogel JU; Kornhuber B; Schwabe D
    Anticancer Res; 2000; 20(2A):853-9. PubMed ID: 10810366
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
    Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
    Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells.
    Tyagi AK; Agarwal C; Chan DC; Agarwal R
    Oncol Rep; 2004 Feb; 11(2):493-9. PubMed ID: 14719089
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel anionic dendrimer for improved cellular delivery of antisense oligonucleotides.
    Hussain M; Shchepinov M; Sohail M; Benter IF; Hollins AJ; Southern EM; Akhtar S
    J Control Release; 2004 Sep; 99(1):139-55. PubMed ID: 15342187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HER2/neu antisense targeting of human breast carcinoma.
    Roh H; Pippin JA; Green DW; Boswell CB; Hirose CT; Mokadam N; Drebin JA
    Oncogene; 2000 Dec; 19(53):6138-43. PubMed ID: 11156527
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor growth inhibition in vivo and G2/M cell cycle arrest induced by antisense oligodeoxynucleotide targeting thymidylate synthase.
    Berg RW; Werner M; Ferguson PJ; Postenka C; Vincent M; Koropatnick DJ; Behrend E
    J Pharmacol Exp Ther; 2001 Aug; 298(2):477-84. PubMed ID: 11454908
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergistic antitumor activity of TRAIL combined with chemotherapeutic agents in A549 cell lines in vitro and in vivo.
    Fan QL; Zou WY; Song LH; Wei W
    Cancer Chemother Pharmacol; 2005 Feb; 55(2):189-96. PubMed ID: 15290100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effect of bcl-2 antisense oligonucleotides on multidrug resistance of cultured uveal melanoma cells].
    Guo LJ; Wu ZY; Zhang S; Zheng JL; Zheng HL
    Zhonghua Yan Ke Za Zhi; 2003 Feb; 39(2):73-6. PubMed ID: 12783683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro effects of MYCN sense and antisense expression in MYCN-amplified human neuroblastoma cells.
    Kavallaris M; Gardaneh M; Cheung B; Camacho ML; Hocker JE; Norris MD; Haber M; Marshall GM
    Anticancer Res; 1998; 18(3A):1793-7. PubMed ID: 9673406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antisense oligonucleotides.
    Herdewijn P
    Verh K Acad Geneeskd Belg; 1996; 58(4):359-81. PubMed ID: 8956554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sensitization of HER-2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin.
    Zhang L; Hung MC
    Oncogene; 1996 Feb; 12(3):571-6. PubMed ID: 8637714
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting tumor cell resistance to apoptosis induction with antisense oligonucleotides: progress and therapeutic potential.
    Olie RA; Zangemeister-Wittke U
    Drug Resist Updat; 2001 Feb; 4(1):9-15. PubMed ID: 11512155
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single-stranded phosphodiester and phosphorothioate oligonucleotides bind actinomycin D and interfere with tumor necrosis factor-induced lysis in the L929 cytotoxicity assay.
    Stull RA; Zon G; Szoka FC
    Antisense Res Dev; 1993; 3(3):295-300. PubMed ID: 8286930
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The heterogenous cytotoxic response of colon cancer cells is unrelated to phenotypic differentiation characteristics.
    Drewinko B; Yang LY
    Anticancer Res; 1988; 8(1):161-4. PubMed ID: 3128957
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of uptake, degradation and toxicity of antisense ODNs in cancer cells.
    Capaccioli S; Quattrone A; Basi G; Schiavone N; Giannini C
    Nucleic Acids Symp Ser; 1991; (24):299. PubMed ID: 1841356
    [No Abstract]   [Full Text] [Related]  

  • 36. Loss in cell killing effectiveness of anticancer drugs in human gastric cancer clones due to recovery from potentially lethal damage in vitro.
    Barranco SC; Townsend CM
    Cancer Res; 1986 Feb; 46(2):623-8. PubMed ID: 2416429
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of toxicity of intravitreal antineoplastic drugs.
    Peyman GA; Greenberg D; Fishman GA; Fiscella R; Thomas A
    Ophthalmic Surg; 1984 May; 15(5):411-3. PubMed ID: 6203076
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synergistic effects of combination therapy employing antisense oligonucleotides with traditional chemotherapeutics in the PC-3 prostate cancer model.
    Tsui P; Rubenstein M; Guinan P
    Med Oncol; 2004; 21(4):339-48. PubMed ID: 15579918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Melanin inhibits cytotoxic effects of doxorubicin and daunorubicin in MOLT 4 cells.
    Svensson SP; Lindgren S; Powell W; Green H
    Pigment Cell Res; 2003 Aug; 16(4):351-4. PubMed ID: 12859618
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical problems of optimum bioavailability, in particular in cytostatic therapy (author's transl)].
    Gross R; Hirschmann WD
    Arzneimittelforschung; 1976; 26(1A):130-5. PubMed ID: 947192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.